Fabio
5.1 KiB
5.1 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Pharmaceutical Substance Manufacturing Grant Fund; created. | Pharmaceutical Substance Manufacturing Grant Fund. Establishes the Pharmaceutical Substance Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $34 million per fiscal year and in an aggregate amount not to exceed $191,255,000, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $4 billion and create and maintain at least 500 new full-time jobs. This bill is identical to SB 527. | us/states/va | Virginia General Assembly | 2026 | HB 1076 | Virginia HB 1076 (2026) |
|
enacted |
|
2 | 27 | 6 | 2026-01-14 | 2026-04-13 | openstates | ocd-bill/a64e4dbc-7307-4e92-aa49-2f1738a9cf47 | https://lis.virginia.gov/bill-details/20261/HB1076 | 387ef277c3b1cc584035850ecd9fa5f964f09f0637cc622e902375c9ec1e9812 | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
Virginia HB 1076 (2026) — Pharmaceutical Substance Manufacturing Grant Fund; created.
Pharmaceutical Substance Manufacturing Grant Fund. Establishes the Pharmaceutical Substance Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $34 million per fiscal year and in an aggregate amount not to exceed $191,255,000, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $4 billion and create and maintain at least 500 new full-time jobs. This bill is identical to SB 527.
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
Votes
- Reported from Appropriations — 21–0 (pass) · lower
- Reported from Finance and Appropriations — 13–0 (pass) · upper
- H VOTE: — 92–5 (pass) · lower
- Passage R — 39–0 (pass) · upper
- Constitutional reading dispensed (on 2nd reading) — 38–0 (pass) · upper
- Subcommittee recommends reporting — 5–0 (pass) · lower
Sponsors
- Amy J. Laufer — primary (person)
- Katrina Callsen — cosponsor (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2026-01-14 Prefiled and ordered printed; Offered 01-14-2026 26102903D
filing, introduction - 2026-01-14 Referred to Committee on Appropriations
referral-committee - 2026-01-22 Assigned HAPP sub: Commerce Agriculture & Natural Resources
referral-committee - 2026-01-23 Fiscal Impact Statement from Department of Planning and Budget (HB1076)
- 2026-01-28 Subcommittee recommends reporting (5-Y 0-N)
- 2026-01-30 Reported from Appropriations (21-Y 0-N)
committee-passage - 2026-02-03 Read first time
reading-1 - 2026-02-04 Moved from Uncontested Calendar to Regular Calendar
- 2026-02-04 Read second time and engrossed
reading-2 - 2026-02-05 Read third time and passed House (92-Y 5-N 0-A)
passage, reading-3 - 2026-02-06 Constitutional reading dispensed (on 1st reading)
- 2026-02-06 Referred to Committee on Finance and Appropriations
referral-committee - 2026-02-17 Reported from Finance and Appropriations (13-Y 0-N)
committee-passage - 2026-02-18 Read second time
reading-2 - 2026-02-18 Rules suspended
- 2026-02-18 Constitutional reading dispensed Block Vote (on 2nd reading) (38-Y 0-N 0-A)
- 2026-02-18 Passed by for the day
- 2026-02-19 Read third time
reading-3 - 2026-02-19 Passed Senate Block Vote (39-Y 0-N 0-A)
passage - 2026-02-23 Enrolled
enrolled - 2026-02-23 Bill text as passed House and Senate (HB1076ER)
passage - 2026-02-23 Fiscal Impact Statement from Department of Planning and Budget (HB1076)
- 2026-02-23 Signed by Speaker
passage - 2026-02-23 Signed by President
passage - 2026-03-10 Enrolled Bill communicated to Governor on March 10, 2026
enrolled, executive-receipt - 2026-03-10 Governor's Action Deadline 11:59 p.m., April 13, 2026
executive-receipt - 2026-04-13 Approved by Governor-Chapter 808 (effective 7/1/2026)
executive-signature
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/a64e4dbc-7307-4e92-aa49-2f1738a9cf47. Confidence: reported (aggregated from official Virginia legislature records).